Compare LyondellBasell Industries NV (LYB) vs Novavax Inc (NVAX) Price & Performance

LyondellBasell (LYB) trades at $58.49, down 0.75% on the day, amid a bearish technical signal and mixed fundamentals. The company reported a net loss of $745 million in 2025, with negative profit margins, though recent quarterly EPS beats and a consensus price target of $69.38 suggest recovery potential. Cash flow remains positive, and a $0.69 dividend is scheduled for payment on August 31, 2026, but declining revenue and high debt levels pose challenges.

The outlook for LYB hinges on earnings recovery and cost management, with analyst sentiment evenly split between buy and hold. Key risks include volatile chemical markets and high leverage, while institutional activity shows mixed positioning. The stock offers value based on P/S and P/B ratios but requires monitoring of profitability trends and debt sustainability for sustained upside.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.